In This Issue
Cancer Discov December 1 2011 1 (7) 539-540; DOI:10.1158/2159-8290.CD-ITI11-07
An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.
An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.
Dedifferentiated liposarcomas harbor recurring HDAC1 mutations and exhibit aberrant methylomes, suggesting that epigenetic therapies may be effective in these tumors.
Objective, long-lasting responses are observed in patients with NSCLC treated with azacitidine and entinostat.
Overexpression of the CRKL adaptor protein activates oncogenic signaling pathways and promotes drug resistance in NSCLC.